Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, randomised, multicenter study to assess the efficacy and safety of HuM195 (recombinant humanized anti-CD33 monoclonal antibody) in combination with standardized chemotherapy compared to standardized chemotherapy alone in the treatment of patients with refractory or first-relapsed acute myelogenous leukemia (AML).

Next Previous
X
Search
Trial Profile

Phase III, randomised, multicenter study to assess the efficacy and safety of HuM195 (recombinant humanized anti-CD33 monoclonal antibody) in combination with standardized chemotherapy compared to standardized chemotherapy alone in the treatment of patients with refractory or first-relapsed acute myelogenous leukemia (AML).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lintuzumab (Primary) ; Cytarabine; Etoposide; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 11 Sep 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top